People in Connecticut with multiple sclerosis may be interested to learn of a drug that was recently denied approval by the Food and Drug Administration. The drug, Lemtrada, has been approved for use in countries other than the United States. Here in America, however, FDA officials say the drug's benefits do not outweigh its potential for harm.
For many people suffering with multiple sclerosis, a loss of memory is a significant byproduct of the disease. Many of their medications have to be taken daily or multiple times a day. With Lemtrada, the medication is taken only one or two times a year.